Skip to content
MenuOpen navigation menu

Real moms, real GLP-1 talk

The GLP-1 Timeline: What Actually Happens Month by Month

How to read a GLP-1 treatment timeline without turning trial averages into personal deadlines, with questions about symptoms, dose reviews and maintenance.

Written by — editorial research, not medical advice
On this page

The honest version of the timeline

I would use a treatment timeline to organize questions, not to predict a deadline for my body. Starting dose, tolerability and treatment changes affect what an individual notices. The trials describe averages over months; they do not tell me that my appetite or weight must change in a particular week. That is the distinction I would keep beside any month-by-month chart.

Some links here earn us a referral fee, and I'll flag our featured partner.

Month 1: starting and checking tolerability

Month one is deliberately underwhelming. These programs start you at a low "starter" dose and step it up slowly on purpose, so your gut has time to adjust — the semaglutide (Wegovy) schedule begins at 0.25 mg a week and climbs in stages over 16 weeks before you ever reach the full maintenance dose3, and tirzepatide (Zepbound) starts at 2.5 mg with a 20-week dose-escalation runway built into its trial2.

A small change in the first four weeks does not, by itself, establish treatment failure, and a first month taken week by week looks nothing like the long-term trial averages. Appetite may change before weight is clearly different, but that is not a timetable everyone follows5. I would ask my clinician how to assess tolerability and response at the starter dose, and what should prompt contact before the planned review.

Months 2–3: dose changes and symptom checks

This is where the two things happen at once. Your dose keeps stepping up toward a maintenance level, and the weight loss becomes visible. It's also, honestly, when side effects are most likely — the gastrointestinal stuff (nausea, sometimes constipation or looser stools) clusters during the escalation phase rather than at a steady dose2. In the big trials these effects were typically mild-to-moderate and subsided with time1, but "mild" while parenting is still a lot, so I'd plan lighter meals and protect your hydration through this window.

By around the end of the run-in period, the numbers are real. In the semaglutide maintenance study, people hit roughly 10.6% average weight loss by week 20 — that's the first-few-months payoff, not the finish line4.

Dose changes can have a billing consequence, depending on the service and plan. CoreAge Rx, our featured partner, advertises one flat monthly price at every listed dose, and Sprout Health also keeps its price flat as the dose escalates. bmiMD advertises the same price at every dose too, but its monthly plans renew every 28 to 30 days, so a year can hold more than twelve charges. The billing unit is not always clear either: Embody's terms list semaglutide at $79 a month, but its storefront pages are gone and its homepage describes week-based plans. So I would ask for the total at the expected dose, any required visit fee and the renewal amount rather than assume the advertised starting price is my ongoing bill.

Months 4–6: the steady-state stretch

Once you're at your maintenance dose, the drama settles and the work becomes consistency. The loss keeps coming, just more gradually — this is the long, unglamorous middle where the weekly shot is routine and the scale trends down in smaller increments. Refill timing becomes part of that routine, and not every seller counts in months: Live Vital sells tirzepatide as a $549 ten-week protocol, so I would map its refill dates onto my own calendar. It's genuinely the phase where most people either build the habit or drift, and where I'd tell a friend to stop weighing daily and start weighing the trend.

Which molecule you're on matters for the pace here, and the Zepbound vs Wegovy choice carries mom-specific angles too, like breastfeeding timing and birth control. In the head-to-head research, tirzepatide's higher doses drove more weight loss than semaglutide — worth knowing if you're still choosing.

Months 6–12 and beyond: keep the trial timescale clear

This is the destination the famous statistics describe. Once-weekly semaglutide reached about 14.9% mean body-weight loss at 68 weeks, with roughly half of participants losing 15% or more1. Higher-dose tirzepatide went further — around 20.9% at 72 weeks on the 15 mg dose2. Those are the "before and after" numbers, and notice the timeline: they're measured at 15 to 17 months, not month three. The internet compressed a year-plus of slow progress into a slider, and that's why everyone feels behind.

The loss also isn't linear. A genuine GLP-1 plateau, when the scale stalls for weeks at a steady dose, is a separate question to raise with the prescriber. The ordinary pattern is a curve: loss is steepest in the early-to-middle months and flattens as you approach your body's new set point, which is completely normal and not a sign the drug quit.

The part the timeline charts leave out: it's not a cure

Here's the piece I wish someone had front-loaded for me. The weight loss is a treatment effect, not a reset. In the maintenance trial, people who kept taking semaglutide after week 20 continued losing (another ~7.9% through week 68), while those switched to placebo regained about 6.9%4. Translation: this is a chronic-condition medication, the timeline doesn't have a clean "done," and what happens when you stop a GLP-1 belongs in the plan from the start. That's not a scare — it's the single most important thing to build your expectations and your budget around.

The questions I would put beside the calendar

  • Month 1: Is my prescribed dose clear, and can I eat and drink adequately?
  • Months 2–3: How are my symptoms and treatment response being reviewed before any increase?
  • Months 4–6: Is my plan sustainable, including the routine and the recurring cost without insurance?
  • Later follow-up: Which health changes matter alongside the scale, and what should my maintenance plan include?
  • If I need to stop: Whom do I contact, and what monitoring or support should I arrange?

Your timeline, your history, and your dose belong in a conversation with your own clinician — not a chart.

Frequently asked questions

When will I actually start losing weight on a GLP-1?

There is no universal starting week. Early doses allow assessment of tolerability, while the well-known trial averages describe outcomes over many months. Ask your clinician how response will be assessed at your current dose rather than turn a long-term average into a month-one target.

Why has my weight loss slowed down after several months?

Trial curves often show the average rate of weight loss slowing over time. That does not establish why a particular person has stalled or prove the medication is working or failing. Discuss the trend, dose, tolerability, nutrition and other changes with the prescriber before adjusting treatment.

Is the weight loss permanent once I hit my goal?

It's a treatment effect, not a one-time reset. In a maintenance trial, people who kept taking semaglutide continued losing, while those switched to placebo regained a meaningful share of their loss. Plan for a GLP-1 as a long-term, chronic-condition medication and decide any changes with your clinician.

References

  1. Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/33567185/
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. https://pubmed.ncbi.nlm.nih.gov/35658024/
  3. Novo Nordisk (FDA prescribing information, via DailyMed) (2025). WEGOVY (semaglutide) injection — Dosage and Administration (titration schedule). U.S. National Library of Medicine, DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
  4. Rubino D, Abrahamsson N, Davies M, et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA. https://pubmed.ncbi.nlm.nih.gov/33755728/
  5. Singh G, Krauthamer M, Bjalme-Evans M. (2022). Wegovy (semaglutide): a new weight loss drug for chronic weight management. Journal of Investigative Medicine. https://pubmed.ncbi.nlm.nih.gov/34706925/

One mom to another, not a doctor: everything here is for learning and figuring out your options, not medical advice, a diagnosis, or a plan for your body. Pregnancy planning and breastfeeding need advice for the exact medicine and formulation. Before you start, stop, or change anything, talk it through with a clinician who actually knows your history.